Management of Severe Malaria

Jorge Hidalgo, Pedro Arriaga, and Gloria M. Rodriguez-Vega

Case Presentation

A 25-year-old male presented to the emergency department with a history of abdominal pain in the right hypochondrium, jaundice, fever, and a decrease in consciousness. He recently returned from Nigeria, where he spent three weeks traveling for business. Laboratory tests at presentation showed WBC: 20,650, Neu:88, Lymph:12, Platelets: 38,000, SGOT: 88, SGPT: 120, Total Bilirubin: 4.3 mg/dL, Indirect Bilirubin: 2.9 mg/dL, Creatinine 5.6 mg/dL. His urine was visibly dark in color (macroscopic hemoglobinuria see Fig. 64.1) and his examination was notable for multiple ecchymoses. The patient was admitted to the intensive care unit with septic shock. A thick blood smear revealed \( P. falciparum \) malaria. The patient was initiated on IV anti-malaria therapy with quinidine gluconate plus doxycycline. Despite antimalarial drug administration and supportive care, the patient developed acute respiratory distress syndrome and acute renal failure requiring renal replacement therapy.

Question

What are the challenges in the diagnosis and management of the returning traveler with severe malaria?

Answer

People now move across the world with great facility. Endemic diseases, such as malaria, can affect travelers upon return home. Malaria.com maps the regions of the world where \( P. falciparum \), the type intensivists might encounter, may be transmitted [1].

In a returning traveler, fever can be a benign and self-limiting infection, but initially must be considered seriously. Table 64.1 displays the top illnesses encountered in returning travelers. In order to make a diagnosis a comprehensive history with details regarding places visited, duration, purpose, and activities undertaken. Chemoprophylaxis taken before or while traveling is a critical component of the history for the initial work-up. Knowledge of incubation period and disease risk by geographic are helpful in making a differential diagnosis. Table 64.2 displays various diseases potentially encountered by the returning traveler by the duration of the incubation period.
Principles of Management

Patients with severe malaria usually present with a high level of parasitemia or significant signs of organ dysfunction. Populations at the highest risk for severe falciparum malaria are young children, pregnant women, and travelers to endemic areas. In endemic areas, elder children and adults develop partial immunity after repeated infections and are at relatively low risk for severe disease. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and are at high risk for severe disease. Pregnant women are more likely to develop severe *P. falciparum* malaria than other adults, particularly in the second and third trimesters. Complications such as hypoglycemia and pulmonary edema are more common than in non-pregnant individuals. Maternal mortality can approach 50%, and fetal death and premature labor are common [3].

**Definition of Severe Malaria**

Severe malaria is generally defined as acute malaria with high levels of parasitemia (>5%) and/or significant signs of organ dysfunction which may include:
1. Altered consciousness with or without convulsions
2. Use of accessory muscles, nasal flaring, tachypnea
3. Metabolic acidosis
4. Circulatory collapse
5. Pulmonary edema or acute respiratory distress syndrome (ARDS)
6. Renal failure, hemoglobinuria (“Blackwater Fever”)
7. Jaundice
8. Disseminated Intravascular Coagulation
9. Severe Anemia
10. Hypoglycemia

**Diagnosis**

The clinician must have a high index of suspicion for malaria in travelers presenting with fever and a history of travel to malaria-endemic regions within the previous year and especially in the prior 3 months. In uncomplicated malaria, apart from fever, patients usually present with nonspecific clinical features. If the diagnosis of falciparum malaria has been delayed, a seemingly well-appearing patient may rapidly deteriorate and present with jaundice, confusion, or seizures and have a high fatality rate. Hence, it is critical to make a rapid and accurate diagnosis when malaria is suspected clinically [4, 5].

Microscopy is the gold standard and preferred option for the diagnosis of malaria. In most cases, the examination of thin and thick blood films will reveal Malaria parasites (Figs. 64.3 and 64.4). Thick films are more sensitive to detect low levels of parasitemia. In general, the higher the parasite density in the peripheral blood, the higher the likelihood that severe disease is present or will develop, especially in immunocompromised patients. Thick smears are more sensitive diagnostically, but the thin smear subsequently helps in determining the malaria species and the level of parasitemia (the percentage of a patient’s red blood cells infected with malaria parasites).

**Clinical Management**

**General Principles**

Most of the time uncomplicated malaria has a good prognosis with a case fatality less than 0.1%. Uncomplicated malaria caused by *P. ovale*, *P. vivax*, and *P. malariae* can usually be managed with oral drugs on an outpatient basis, unless a patient has other comorbidities or is unable to take drugs orally [5, 7]. However, a severe disease requiring ICU admission can occur in patients with *P. vivax* or *P. knowlesi* [8]. In one series a higher percentage of patients with *P. vivax* required ICU admission that *P. falciparum* and the mortality was higher (22.9% versus 5.6%, p < 0.05), with ARDS being nearly twice as common in the *P. vivax* patients (45.7% versus 23.3%, p = 0.06) [9]. In patients with *P. vivax* respiratory decom-
Compensation may be preceded by administration of antimalarials and progress rapidly [10].

Due to little immunity against these infections, *P. falciparum* infections in travelers can rapidly progress to severe illness or death in as little as 1–2 days, so rapid assessment and initiation of antimalarial therapy is essential. Patients should be evaluated with attention to findings consistent with malaria as well as additional and/or alternative causes of presenting symptoms. Of primary importance in the treatment of malaria is the provision of prompt, effective therapy and concurrent supportive care to manage life-threatening complications of the disease. Supportive measures, such as fluid management, oxygen, ventilatory support, cardiac monitoring, and pulse oximetry, should be instituted as needed. During this time, intravenous access should be obtained immediately. Point-of-care testing can be used for rapid determination of hematocrit, glucose, and lactate. Parasitemia can also be determined quickly but requires a microscope. Additional tests can be done if/when indicated: electrolytes, full blood count, type and cross, blood culture, and clotting studies. Unconscious patients should have a lumbar puncture to rule out concomitant bacterial meningitis in the absence of contraindications (i.e., papilledema). These tasks should overlap with an institution of antimalarial treatment as well as other ancillary therapies as needed (including anticonvulsants, intravenous glucose and fluids, antipyretics, antibiotics, and blood transfusion) [11, 12].

Repeat clinical assessments should be performed every 2–4 h for timely detection and management of complications in an intensive care setting, if possible. If the Glasgow Coma Score (or in children the Blantyre coma score [see Table 64.3]) decreases after initiation of treatment, the investigation should focus on the possibility of seizures, hypoglycemia, or worsening anemia. Repeat laboratory assessments of parasitemia, hemoglobin/hematocrit, glucose, and lactate should be performed in 6-h intervals. A flow chart summarizing the vital information may be used to guide management decisions [11–13].

Significant independent predictors for fatality among African children with severe malaria include acidosis, impaired consciousness (coma and/or convulsions), elevated blood urea nitrogen, and signs of chronic disease (lymphadenopathy, malnutrition, candidiasis, severe visible wasting, and desquamation). Clinical features previously identified as being poor prognostic features that did not correlate with mortality in this study included age, glucose level, axillary temperature, parasite density, and Blackwater Fever [14–16].

Careful observation and thoughtful responses to changes in clinical status are the most critical elements in looking after patients with severe malaria. Patients can make remarkable recoveries, and the time and effort to address the components of clinical care described in the following sections can reap tangible rewards in a relatively short period of time.

Clinical evaluation includes a full physical exam, a complete neurologic examination, calculation of Glasgow or Blantyre coma score (Table 64.3), and funduscopic evaluation. Malarial retinopathy is pathognomonic for cerebral malaria in patients who satisfy the standard clinical case definition (Fig. 64.5).

![Figure 64.5](https://placeHolder.com/)

**Table 64.3** Blantyre coma score

| Type of response | Response                          | Score |
|-----------------|----------------------------------|-------|
| Best motor      | Localize painful stimulus        | 2     |
|                 | Withdraws limbs from pain        | 1     |
|                 | Nonspecific or absent response   | 0     |
| Verbal          | Appropriate cry                  | 2     |
|                 | Moan or inappropriate cry        | 1     |
|                 | None                             | 0     |
| Eye movements   | Eg: Directed (follows mother’s face) | 1    |
|                 | Not directed                     | 0     |
| Total           |                                  | 0–5   |

The Blantyre coma scale is a modification of the Pediatric Glasgow Coma Scale, designed to assess malarial coma in children designed by Drs. Terrie Taylor and Malcolm Molyneux in 1987, and named for the Malawian city of Blantyre, site of the Blantyre Malaria Project.
Patients with altered sensorium should undergo a lumbar puncture (in the absence of contraindications) to exclude concomitant bacterial meningitis. If clinical instability or papilledema on ocular fundus examination preclude lumbar puncture, presumptive antibiotic therapy for bacterial meningitis should be initiated.

**Antimalarial Therapy (See Treatment Table 64.4)**

**Monitoring Parasite Density**

Parasitemia should be monitored during treatment to confirm adequate response to therapy. The CDC recommends daily repeat blood smear to document declining parasite density until negative or until treatment day 7 (if discharged before complete parasitemia clearance). During treatment of severe malaria, parasite density should be monitored every 12 h during the first 2–3 days or until negative; some recommendations suggest switching from parenteral to oral therapy as tolerated after parasitemia falls below 1% [15, 16].

**Respiratory System**

Hypoxemia and rales are not common in the setting of severe malaria; the presence of either should raise suspicion for a concomitant lower respiratory tract infection. Pulmonary edema may develop, particularly in the settings of renal impairment or severe malarial anemia. Acute respiratory distress syndrome (ARDS) can also complicate severe malaria.

Deep breathing (Kussmaul respirations) is a clinical indicator of metabolic acidosis and is associated with a worse outcome in patients with falciparum malaria [15, 16].

**Neurologic Involvement**

The standard clinical case definition of cerebral malaria includes the following criteria:

1. Blantyre coma score ≤ 2
2. *P. falciparum* parasitemia (any density)
3. No other identifiable cause of coma (e.g., hypoglycemia, meningitis, or a post-ictal state)

The histologic hallmark of cerebral malaria is cerebral sequestration of parasitized erythrocytes.

Establishing whether retinopathy is present is an essential marker for cerebral malaria. In the absence of this finding, alternative causes for coma (such as bacterial infection) should be pursued and treated, even in the presence of established malaria infection [16, 18].

**Seizure Management**

Seizures occur in up to 70% of children with severe malaria; subclinical seizures occur in 15–20% of cases. Seizures may be generalized or focal, and the clinical signs may be subtle (nystagmus, irregular respirations, hypoventilation, or a drop in the Blantyre coma score). It is also essential to evaluate for causes of seizure besides cerebral malaria (e.g., hypoglycemia, fever) and to treat accordingly as outlined in the following sections.

Benzodiazepines are useful first-line agents for seizure treatment. Diazepam (0.4 mg/kg) can be administered intravenously or per rectum; lorazepam (0.1 mg/kg) can be administered intravenously or intraosseously. These doses can be repeated once if seizures do not cease within 5 min of the initial dose. Benzodiazepines should not be combined due to the risk of respiratory depression. If seizures are not controllable with benzodiazepines, other options include phenobarbitone (phenobarbital 15–20 mg/kg, slow IV push) or phenytoin (18 mg/kg diluted in 100 mL normal saline, infused over 20 min).

If seizures recur, repeat single doses of a benzodiazepine may be administered. Alternatively, maintenance doses of phenobarbital (5–15 mg/kg/day, administered orally, via NG tube, or via slow IV push in divided doses every 12 h) or phenytoin (10 mg/kg/day IV in divided doses every 12 h) may be initiated.

Paraldehyde has been used as an intramuscular injection to treat seizures in the setting of severe malaria (0.2–0.4 mL/kg); its main advantage is that it does not cause respiratory suppression. The cost of this agent has increased dramatically, and it is therefore out of reach for many formularies in malaria-endemic areas.

Patients with severe malaria should not receive routine seizure prophylaxis in the absence of clinical seizure activity [18–20].

**Anemia and Coagulopathy**

Severe hemolysis, which is mainly extravascular, occurs in hyperparasitemia falciparum malaria. Removal of both infected and uninfected erythrocytes from the circulation, mainly by the spleen, is associated with the rapid development of anemia. Patients with severe anemia may present with or without altered consciousness; in addition, severe
Table 64.4  Guidelines for Treatment of Malaria in the United States (Based on drugs currently available for use in the United States—April 1, 2019)

| Clinical diagnosis/ Plasmodium species | Region infection acquired | Recommended drug and adult dose | Recommended drug and pediatric dose |
|----------------------------------------|--------------------------|--------------------------------|-------------------------------------|
| Uncomplicated malaria/ *P. falciparum* or species not identified | Chloroquine-resistant or unknown resistance (All malarious regions except those specified as chloroquine-sensitive listed in the box below.) | A. Atovaquone-proguanil (*Malaraone™*)<sup>a,d</sup>  
Adult tab = 250 mg atovaquone/100 mg proguanil  
4 adult tabs po qd × 3 days | A. Atovaquone-proguanil (*Malaraone™*)<sup>a,d</sup>  
Adult tab = 250 mg atovaquone/100 mg proguanil  
Peds tab = 62.5 mg atovaquone/25 mg proguanil  
5–8 kg: 2 peds tabs po qd × 3 days  
9–10 kg: 3 peds tabs po qd × 3 days  
11–20 kg: 1 adult tab po qd × 3 days  
21–30 kg: 2 adult tabs po qd × 3 days  
31–40 kg: 3 adult tabs po qd × 3 days  
> 40 kg: 4 adult tabs po qd × 3 days |
| | | B. Artemether-lumefantrine (*Coartem™*)<sup>e</sup>  
1 tablet = 20 mg artemether/120 mg lumefantrine  
A 3-day treatment schedule with a total of 6 oral doses is recommended for both adult and pediatric patients based on weight. The patient should receive the initial dose, followed by the second dose 8 h later, then 1 dose po bid for the following 2 days.  
5 to <15 kg: 1 tablet per dose  
15 to <25 kg: 2 tablets per dose  
25 to <35 kg: 3 tablets per dose  
≥35 kg: 4 tablets per dose | |
| | | C. Quinine sulfate<sup>f</sup> plus one of the following: Doxycycline<sup>g</sup>, Tetracycline<sup>g</sup>, or Clindamycin  
Quinine sulfate: 542 mg base (= 650 mg salt) po tid × 3 or 7 days<sup>h</sup>  
Doxycycline: 100 mg po bid × 7 days  
Tetracycline: 250 mg po qid × 7 days  
Clindamycin: 20 mg base/kg/day po divided tid × 7 days | C. Quinine sulfate<sup>f</sup> plus one of the following: Doxycycline<sup>g</sup>, Tetracycline<sup>g</sup> or Clindamycin  
Quinine sulfate: 8.3 mg base/kg (= 10 mg salt/kg) po tid × 3 or 7 days<sup>h</sup>  
Doxycycline: 2.2 mg/kg po every 12 h × 7 days  
Tetracycline: 25 mg/kg/day po divided qid × 7 days  
Clindamycin: 20 mg base/kg/day po divided tid × 7 days |
| | | D. Mefloquine<sup>i</sup>  
684 mg base (= 750 mg salt) po as initial dose, followed by 456 mg base (= 500 mg salt) po given 6–12 h after initial dose  
Total dose = 1250 mg salt | D. Mefloquine<sup>i</sup>  
13.7 mg base/kg (= 15 mg salt/kg) po as initial dose, followed by 9.1 mg base/kg (= 10 mg salt/kg) po given 6–12 h after initial dose. Total dose = 25 mg salt/kg |

Uncomplicated malaria/ *P. malariae* or *P. knowlesi*  
*All regions<sup>j</sup>* | Chloroquine phosphate (*Aralen™* and generics)  
600 mg base (= 1000 mg salt) po immediately, followed by 300 mg base (= 500 mg salt) po at 6, 24, and 48 h  
Total dose: 1500 mg base (= 2500 mg salt) OR  
Hydroxychloroquine (*Plaquenil™* and generics)  
620 mg base (= 800 mg salt) po immediately, followed by 310 mg base (= 400 mg salt) po at 6, 24, and 48 h  
Total dose: 1550 mg base (= 2000 mg salt) | Chloroquine phosphate (*Aralen™* and generics)  
10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 h  
Total dose: 25 mg base/kg OR  
Hydroxychloroquine (*Plaquenil™* and generics)  
10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 h  
Total dose: 25 mg base/kg |

If “species not identified” is subsequently diagnosed as *P. vivax* or *P. ovale*; see *P. vivax* and *P. ovale* (below) re. treatment with primaquine or tafenoquine.
### Uncomplicated Malaria: P. vivax or P. ovale

**All regions**

Note: for suspected chloroquine-resistant *P. vivax*, see row below

| Treatment                                                                 | Note                                                                 | Chloroquine-resistant* (Papua New Guinea and Indonesia)                                                                 |
|--------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Chloroquine phosphate plus either Primaquine phosphate or Tafenoquine (Krintafel™) | Note: OR for all trimesters OR for all trimesters                        | A. Quinine sulfate plus either Doxycycline or Tetracycline plus either Primaquine phosphate or Tafenoquine (Krintafel™) |
| Chloroquine phosphate: Treatment as above                                | Note: OR for all trimesters OR for all trimesters                        | Quinine sulfate: Treatment as above                                                                                  |
| Primaquine phosphate: 30 mg base po qd × 14 days                         | Note: OR for all trimesters OR for all trimesters                        | Doxycycline or Tetracycline: Treatment as above                                                                       |
| Tafenoquine: 300 mg po × 1 dose                                          | Note: OR for all trimesters OR for all trimesters                        | Primaquine phosphate: Treatment as above                                                                             |
| OR                                                                       | Note: OR for all trimesters OR for all trimesters                        | Tafenoquine (Krintafel™): Treatment as above                                                                        |
| Hydroxychloroquine plus Primaquine phosphate                             | Note: OR for all trimesters OR for all trimesters                        | A. Quinine sulfate: Treatment as above                                                                              |
| Hydroxychloroquine: Treatment as above                                    | Note: OR for all trimesters OR for all trimesters                        | Doxycycline or Tetracycline: Treatment as above                                                                      |
| Primaquine phosphate: 30 mg base po qd × 14 days                         | Note: OR for all trimesters OR for all trimesters                        | Primaquine phosphate: Treatment as above                                                                            |
| Tafenoquine: 300 mg po × 1 dose                                          | Note: OR for all trimesters OR for all trimesters                        | Tafenoquine (Krintafel™): Treatment as above                                                                        |

*Can be used instead of primaquine in children 16 years and older: 300 mg po × 1 dose*

### Uncomplicated Malaria: Chloroquine-resistant

*Note: for pregnant women, see sections above for regions with chloroquine-sensitive malaria species*

| Chloroquine phosphate: Treatment as above                                | Note: OR for all trimesters OR for all trimesters                        |
|--------------------------------------------------------------------------|----------------------------------------------------------------------|
| Artemether-lumefantrine (Coartem™)†: Treatment as above                  | Note: OR for all trimesters OR for all trimesters                        |
| Mefloquine: Treatment as above                                            | Note: OR for all trimesters OR for all trimesters                        |

*Not applicable*

### Uncomplicated Malaria: Alternatives for Pregnant Women

*Note: for regions with chloroquine-resistant malaria species*

| Chloroquine phosphate: Treatment as above                                | Note: OR for all trimesters OR for all trimesters                        |
|--------------------------------------------------------------------------|----------------------------------------------------------------------|
| Artemether-lumefantrine (Coartem™)†: Treatment as above                  | Note: OR for all trimesters OR for all trimesters                        |
| Mefloquine: Treatment as above                                            | Note: OR for all trimesters OR for all trimesters                        |

*Note: OR for all trimesters OR for all trimesters                        |
| Quinine sulfate plus Clindamycin: Treatment as above                   | Note: OR for all trimesters OR for all trimesters                        |

*Note: OR for all trimesters OR for all trimesters                        |
Table 64.4 (continued)

| Clinical diagnosis/Region infection acquired | Plasmodium species | Recommended drug and adult dose<sup>a</sup> | Recommended drug and pediatric dose<sup>b</sup> |
|---------------------------------------------|---------------------|--------------------------------------------|------------------------------------------------|
| Severe malaria<sup>++</sup>                  | All regions         | **Intravenous (IV) Artesunate available under an expanded access investigational new drug (IND) protocol (Call CDC):** Give 2.4 mg/kg per dose. Administer one dose at 0, 12, 24, and 48 h for a total of four doses. AND Follow artesunate by one of the following: Artemether-lumefantrine (Coartem™), Atovaquone-proguanil (Malarone™), Doxycycline (Clindamycin in pregnant women), or if no other options, Mefloquine. **Artemether-lumefantrine (Coartem™):** Treatment as above. **Atovaquone-proguanil (Malarone™):** Treatment as above. **Doxycycline:** Treatment as above. If patient not able to take oral medication, give 100 mg IV every 12 h and then switch to oral doxycycline (as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days. **Clindamycin:** Treatment as above. If patient not able to take oral medication, give 10 mg base/kg loading dose IV followed by 5 mg base/kg IV every 8 h. Switch to oral clindamycin (oral dose as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days. **If needed, give interim treatment until IV artesunate arrives (if oral medications are not tolerated, consider administration via nasogastric tube or after an antiemetic):** **Artemether-lumefantrine (Coartem™):** Treatment as above. **Atovaquone-proguanil (Malarone™):** Treatment as above. **Quinine sulfate:** Dosing as above. **Mefloquine:** Use if other options are not available. Dosing as above. | **IV Artesunate available under an expanded IND protocol (Call CDC):** For children ≥20 kg: Give 2.4 mg/kg per dose. Administer one dose at 0, 12, 24, and 48 h for a total of four doses. For children <20 kg: Give 3.0 mg/kg per dose. Administer one dose at 0, 12, 24, and 48 h for a total of four doses. AND Follow artesunate by one of the following: Artemether-lumefantrine (Coartem™), Atovaquone-proguanil (Malarone™), Doxycycline (Clindamycin in children <8 years old), or if no other options, Mefloquine. **Artemether-lumefantrine (Coartem™):** Treatment as above. **Atovaquone-proguanil (Malarone™):** Treatment as above. **Doxycycline (children ≥8 years old):** Treatment as above. If patient not able to take oral medication, may give IV. For children <45 kg, give 2.2 mg/kg IV every 12 h and then switch to oral doxycycline (dose as above) as soon as patient can take oral medication. For children >45 kg, use same dosing as for adults. For IV use, avoid rapid administration. Treatment course = 7 days. **Clindamycin:** Treatment as above. If patient not able to take oral medication, give 10 mg base/kg loading dose IV followed by 5 mg base/kg IV every 8 h. Switch to oral clindamycin (oral dose as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days. **If needed, give interim treatment until IV artesunate arrives (if oral medications are not tolerated, consider administration via nasogastric tube or after an antiemetic):** **Artemether-lumefantrine (Coartem™):** Treatment as above. **Atovaquone-proguanil (Malarone™):** Treatment as above. **Quinine sulfate:** Dosing as above. **Mefloquine:** Use if other options are not available. Dosing as above. |
Treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance.

When treating chloroquine-sensitive infections, chloroquine and hydroxychloroquine are recommended options. However, regimens used to treat chloroquine-resistant infections may also be used if available. Note that if treating P. vivax or P. ovale infections, primaquine or tafenoquine (after quantitative testing to rule out G6PD deficiency) should also be given.

Primaquine and tafenoquine kill any dormant hypnozoites in the liver, thus prevent relapses of P. vivax and P. ovale infections. Because primaquine and tafenoquine can cause hemolytic anemia in G6PD-deficient persons, quantitative G6PD testing must occur prior to starting treatment with these drugs. For persons with borderline G6PD deficiency, primaquine may be given 45 mg orally one time per week for 8 weeks; consultation with an expert in infectious disease and/or tropical medicine is advised if the alternative regimen is considered in G6PD-deficient persons.

Primaquine and tafenoquine must not be used during pregnancy. Pregnant patients with P. vivax and P. ovale infections should be maintained on chloroquine prophylaxis for the duration of their pregnancy. The chemoprophylactic dose of chloroquine phosphate is 300 mg base (= 500 mg salt) orally once per week. After delivery, pregnant patients who do not have G6PD deficiency should be treated with primaquine or tafenoquine. Primaquine can be used during breastfeeding if the infant is found to have normal G6PD levels. Tafenoquine is not recommended in breastfeeding women.

Note: There are three options (A, B, or C) available for treatment of uncomplicated malaria caused by chloroquine-resistant P. vivax. High treatment failure rates due to chloroquine-resistant P. vivax have been well documented in Papua New Guinea and Indonesia. Rare case reports of chloroquine-resistant P. vivax have also been documented in Burma (Myanmar), India, and Central and South America. Persons acquiring P. vivax infections outside of Papua New Guinea or Indonesia should be started on chloroquine. If the patient does not respond, the treatment should be changed to a chloroquine-resistant P. vivax regimen and CDC should be notified (Malaria Hotline number listed above). For treatment of chloroquine-resistant P. vivax infections, options A, B, and C are equally recommended.

Persons with a positive blood smear OR history of recent possible exposure and no other recognized pathology who have one or more of the following clinical criteria (impaired consciousness/coma, severe normocytic anemia, renal failure, pulmonary edema, acute respiratory distress syndrome, circulatory shock, disseminated intravascular coagulation, spontaneous bleeding, acidosis, hemoglobinuria, jaundice, repeated generalized convulsions, and/or parasitemia of > 5%) are considered to have manifestations of more severe disease. The parasite density can be estimated from the percentage of infected RBCs by examining the thin smear slide under oil immersion magnification where the RBCs are more or less touching (approximately 400 RBCs per field), and should be monitored every 12 h. Severe malaria is most often caused by P. falciparum.

All patients with severe malaria should be treated with IV artesunate. Call CDC for IV artesunate.

Exchange transfusion is no longer recommended based on a systematic review of the literature and analysis of US malaria surveillance data showing no added benefit in severe malaria.
anemia has been associated with long-term neurocognitive impairment. In endemic areas, hemoglobin concentration may decrease gradually throughout repeated malaria infections. As a result, patients can be fully alert with hemoglobin concentrations of 2–3 g/dL (hematocrit < 10%). Evaluation for the pallor of the conjunctivae, nail beds, and palms can provide a rough estimate of the degree of anemia, since blood vessels in these areas are close to the surface.

Hemoglobin concentration and hematocrit are routinely measured components of complete blood counts, but this may not be available in resource-limited settings, or the results may not be available promptly. In such circumstances, the hematocrit can be measured on a finger-prick sample of blood collected into a heparinized capillary tube and centrifuged using a mechanical device. Alternatively, the hemoglobin concentration can be determined from fingerprick samples of blood collected into cuvettes. This method is more expensive than manually spinning a hematocrit, but can be performed readily near the bedside.

Clinically evident disseminated intravascular coagulation in the setting of severe malaria is rare (<5%), but profound thrombocytopenia is common, and the microcirculation in many organs is occluded by fibrin thrombi [21, 22].

**Blood Products**

Blood products should be administered in patients with dire prognoses, i.e., patients with altered consciousness, high output heart failure, respiratory distress, a cold periphery, hyperlactatemia, and/or high-density parasitemia. Laboratory parameters of concern include low hemoglobin concentration (≤4–5 g/dL) or low hematocrit (≤10–15%). The degree of anemia and the level of parasitemia may be useful parameters for predicting the need for a blood transfusion and for determining the volume of blood to transfuse. In general, 10 mL/kg of packed red blood cells or 20 mL/kg of whole blood transfused over 2–4 h is appropriate. Blood should be typed and crossmatched before infusion.

Blood transfusions are generally well-tolerated in the setting of severe malaria since patients are relatively hypovolemic; diuretics are rarely needed. Monitoring of hemoglobin concentration or hematocrit should continue until the parasitemia clears, since repeat transfusion may be required [22].

**Hypoglycemia**

Defined as blood glucose <40 mg/dL or <2.2 mmol/L, hypoglycemia is a common complication of malaria and a marker of severe disease. It should be suspected in any patient who is comatose or who deteriorates suddenly.

The pathogenesis of hypoglycemia is not fully understood; it may be related to parasite glucose consumption and/or impaired host gluconeogenesis. Malnutrition, adrenal insufficiency, and hyperinsulinemia are not likely causes of hypoglycemia. In addition to primary hypoglycemia, administration of quinine or quinidine (insulin secretagogues) can cause iatrogenic hypoglycemia. Hypoglycemia with artesunate therapy is less common than with quinine or quinidine.

Patients presenting with normoglycemia can develop hypoglycemia during treatment. When determining intravenous maintenance fluids, the clinician should consider the possibility of hypoglycemia and use glucose-containing solutions. In addition, those managed promptly for hypoglycemia at presentation can have subsequent recurrent hypoglycemia. Therefore, blood glucose should be monitored closely during illness with prompt management as outlined above. Patients with recurrent hypoglycemia should receive 10% dextrose. Ten percent dextrose can be prepared quickly by withdrawing 100 mL from a one-liter bag of a 5% dextrose solution and replacing it with 100 mL of a 50% dextrose solution [21–23].

**Volume Management**

Adults with malaria appear to be more vulnerable to fluid overload than children. There is a fine line between underhydration, and thus worsening renal impairment, and overhydration, risking pulmonary and cerebral edema. Hence, fluid requirements should be assessed on an individual basis, using commonly employed tools such as delayed capillary refill, low central venous pressure, and low urine output. Deep breathing, reflecting lactic acidosis, may also be a reasonable indicator of hypovolemia [22, 23].

**Nutrition**

Nutritional supplementation should be provided by nasogastric tube (NG) for patients with prolonged coma who are unable to eat and drink within 24–48 h.

**Fever**

High fevers (>38.5 °C) are frequent in the setting of malaria infection and may reflect the host response to endogenous pyrogens released at the time of schizont rupture. The optimal approach to the treatment of fever is uncertain, although the use of antipyretics in patients with high fever is appropriate given the association between high fever and convulsions. Dynamic temperature control may help reduce
long-term neurologic outcomes in pediatric patients with retinopathy-positive cerebral malaria.

Paracetamol (acetaminophen); 15 mg/kg every 6 h; maximum dose 1000 mg) is a reasonable antipyretic agent; oral therapy can be used for patients able to swallow. Otherwise, suppository formulations are acceptable. If fever persists, ibuprofen (10 mg/kg every 6 h; maximum dose 1200 mg per day) can be administered (orally, via nasogastric tube, or intravenously) alone or on an alternating schedule with paracetamol every 3 h [23–25].

**Bacterial Infection**

A concomitant bacterial infection is an essential contributor to morbidity and mortality in the setting of severe malaria, and severe anemia has been implicated as a primary risk factor for non-typhoidal *Salmonella* septicemia. The bacterial infection should be suspected in patients with severe anemia together with signs or symptoms of sepsis (hypotension, cold extremities, delayed capillary refill, hyperlactatemia). In such cases, blood cultures should be obtained, and broad-spectrum antibiotic therapy with activity against gram-negative bacilli should be initiated [24, 25].

**Evidence Contour**

**Other Diagnostic Modalities**

A significant drawback of light microscopy is that the efficiency of the test depends on the type and quality of the smear, skill of the technician, parasite density, and time spent on examining the smear. In addition, mixed infections with *P. malariae* or *P. ovale* are often missed, because their densities are often low in comparison to that of *P. falciparum*. These problems may occur more frequently in non-endemic areas where malaria microscopy is performed infrequently.

**Quantitative Buffy Coat**

Quantitative buffy coat (QBC) is fluorescent microscopy based on the principle of concentrating the red blood cell-containing parasites within a narrow zone by centrifugation of blood in capillary tubes and staining of malarial parasite nucleic acid with acridine dyes. The sensitivity of QBC almost equals that of Giemsa-stained films. The advantage of QBC is ease of interpretation and rapidity. Species identification and quantification are complicated, however, with this technique and, therefore, thick and thin blood film examination is still required. This technique requires the use of expensive fluorescent microscopy equipment for the interpretation of results. This is a significant limitation especially in the poor resource countries [25].

**Antigen Rapid Detection Test (RDT)**

Antigen detection RDTs detect malaria antigen in blood by an immunochromatographic test with monoclonal antibodies directed against the target parasite antigen, which is impregnated on a test strip. The result is usually obtained in 5–20 min. Currently, different combinations of immunochromatographic tests are commercially available, targeting different genus-specific or species-specific antigen for malaria diagnosis. Some of the commonly used antigens in RDTs are HRP-2 (*P. falciparum*-specific), aldolase (pan-specific), *Plasmodium* lactate dehydrogenase (pLDH) (*P. falciparum*-specific), pLDH (*P. vivax*- specific), and pLDH (panspecific) [25, 26].

**Serology**

Serology detection of antibodies against malaria parasites, using either indirect immunofluorescence assay or ELISA, does not indicate current infection but rather measures past exposure. Therefore, it has no role in the diagnosis of acute infections. Serology may be used to screen donors to prevent transfusion-related malaria, however, and to confirm the diagnosis of malaria in recently treated cases in which the diagnosis could not be confirmed previously [25–27].

**Molecular Methods**

Molecular technologies have been developed to improve the diagnosis of malaria by detecting specific parasite nucleic acid. The advantage of molecular methods is their exquisite sensitivity down to the level of 5 parasites/mL or 0.0001% parasitemia [26, 27].

**Exchange Transfusion**

Exchange transfusion has been proposed as a means of removing infected red blood cells from the circulation, thereby lowering the parasite burden and replacing with unparasitized cells. There is no evidence supporting the efficacy of exchange transfusion as adjunctive therapy in severe malaria, and there is no consensus on the indications, approach, benefits, or risks of this procedure.

The CDC no longer recommends exchange transfusion for treatment of severe malaria, based on a review that demonstrated no differences in outcome among patients who
underwent exchange transfusion; previously, the CDC recommended exchange transfusion for patients with parasite density of >10% with end-organ complications. The WHO guidelines indicate that it is not possible to make any recommendations regarding the use of exchange transfusion based on the available evidence. The American Society for Apheresis (ASFA) supports exchange transfusion as adjunctive therapy for patients with >10% parasitemia, although its consideration of adverse events associated with exchange transfusion for malaria is limited [25–27].

References

1. Malaria.com—Uniting Against Malaria. High-risk areas for malaria [Internet]. Cited 4 Apr 2016. http://www.malaria.com/questions/high-risk-areas-malaria-map.

2. Wattal C, Goel N. Infectious disease emergencies in returning travelers: special reference to malaria, dengue fever, and chikungunya. Med Clin North Am. 2012;96:1226.

3. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383:723–35.

4. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2010. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed 30 Dec 2010.

5. Intervention in infectious disease emergencies. Med Clin North Am. 2012;96(6):1225–55.

6. Centers for Disease Control and Prevention (CDC). DPDx – laboratory identification of parasitic diseases of public health concern. http://www.cdc.gov/dpdx/malaria/gallery.html#pfalringformtrophs.

7. White NJ. The treatment of malaria. N Engl J Med. 1996;335:800–6.

8. Karnad DR, Nor MBM, Richards GA. Intensive care in severe malaria: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2018;43:356–60.

9. Trived T, Bajaj P, Moulick N, et al. Mortality in Malaria: Intensive Care (MIMIC). J Assoc Physicians India. 2018;66:16–20.

10. Val F, Avalos S, Gomes AA, et al. Are respiratory complications of Plasmodium vivax malaria and underestimated problem? Malar J. 2017;16:495–20.

11. Crawley J, Chu C, Mtove G, Nosten F. Malaria in children. Lancet. 2010;375:1468–81.

12. Bejon P, Warimwe G, Mackintosh CL, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun. 2009;77:1917–23.

13. Mali S, Steele S, Slutsker L, et al. Malaria surveillance – United States, 2006. MMWR Surveill Summ. 2008;57:24.

14. Phillips A, Bassett P, Zeki S, et al. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis. 2009;48:871–8.

15. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis. 2008;47:151–7.

16. Taylor T, Olola C, Valim C, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg. 2006;100:615–22.

17. Mishra SK, Newton CRJC. Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol. 2009;5(4):189–98.

18. von Seidlein L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in African children: findings from a large randomized trial. Clin Infect Dis. 2012;54:1080–90.

19. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomized trial. Lancet. 2010;376:1647–57.

20. Sinclair D, Donegan S, Isba R, Laloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.

21. Esu E, Effa EE, Opie ON, et al. Artemether for severe malaria. Cochrane Database Syst Rev. 2014;10:CD010678.

22. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med. 2008;358:1829–36.

23. New medication for severe malaria available under an investigational new drug protocol. MMWR Surveill Summ. 2007;56:769. http://www.cdc.gov/mmWR/preview/mmwrhtml/mm5630a5.htm. Accessed on February

24. Sweetman SC, editor. The complete drug reference. 36th ed. London: Pharmaceutical Press. http://www.medicinescomplete.com/. Accessed 05 Mar 2009.

25. World Health Organization. Management of severe malaria: a practical handbook. 3rd ed. Geneva: WHO; 2012. http://apps.who.int/iris/bitstream/10665/79317/1/9789241548526_eng.pdf. Accessed 18 Sept 2013.

26. Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Part 3: alternatives for pregnant women and treatment of severe malaria. http://www.cdc.gov/malaria/diagnosis_treatment/clinicians3.html. Accessed 18 Sept 2013.

27. Centers for Disease Control and Prevention. Treatment of malaria: exchange transfusion for the treatment of severe malaria no longer recommended. http://www.cdc.gov/malaria/new_info/2013/exchange_transfusion.html. Accessed 31 Jan 2014.